Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling
Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling have?
Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling has 75 citations in the OpenAlex counts ScholarIQ stores.
When was Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling published?
Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling has 2023 year in the ScholarIQ index.
What is the open-access status of Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling?
Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling has gold oa status in the ScholarIQ index.
What is the DOI of Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling?
The DOI for Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling is on the source record.
What is the PMID of Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling?
The PMID for Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling is on the source record.
What is the OpenAlex record for Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling?
The OpenAlex for Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling is on the source record.